Table 2.

Comparisons of the rate in which RBV was discontinued, the rate in which RBV dosage was reduced due to development of anemia, 4-week hemoglobin reduction rate from the baseline, the EVR rate and the SVR rate of the patients with 2-week erythrocyte phosphorylated RBV concentration <600 μM to 600–800 μM, and 800 μM ≦.

	<600 μM (n = 7)	600–800 μM (n = 7)	800 μM ≦ (n = 10)
Rate of RBV discontinuation (%)	0/7 (0)	0/7 (0)	3/10 (30.0)
Rate of RBV reduction (%)	1/7 (14.3)	3/7 (42.9)	3/10 (30.0)
ΔHb by 4 weeks (%)	−13.5 ± 8.8	−15.7 ± 6.5	−23.4 ± 11.6
Rate of EVR(%)	0/7 (0)	5/7 (71.4)	6/10 (60.0)
Rate of SVR (%)	0/7 (0)	3/7 (42.6)	3/10 (30.0)

RBV: ribavirin.

ΔHb: 4-week hemoglobin reduction rate from the baseline.

EVR: Early Virological Response; Serum HCV RNA negativity until 12 weeks of therapy.

SVR: Sustained Virological Response; Serum HCV RNA negativity at 24 weeks after completed therapy.

ΔHb is expressed as mean ± S.D.